ERBB2 and breast carcinoma: The phase III BRAVO trial compared the efficacy and safety of niraparib monotherapy to commonly used chemotherapy regimens for patients with gBRCAm and HER2-negative advanced breast cancer but was terminated prematurely due to the high rate of discontinuation in the control arm.